Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label investigator sponsored trial to investigate the safety, tolerability and development of subfoveal fibrosis by intravitreal administration of altering regimens of Fovista (Anti-PDGF-B pegylated aptamer) and Anti-VEGF therapy (Lucentis, Avastin or Eylea in subjects with neovascular age-related macular degeneration

Trial Profile

An open-label investigator sponsored trial to investigate the safety, tolerability and development of subfoveal fibrosis by intravitreal administration of altering regimens of Fovista (Anti-PDGF-B pegylated aptamer) and Anti-VEGF therapy (Lucentis, Avastin or Eylea in subjects with neovascular age-related macular degeneration

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegpleranib (Primary) ; Aflibercept; Bevacizumab; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Feb 2015 Initial results were presented at the 12th Annual Bascom-Palmer Eye Institute Angiogenesis, Exudation, and Degeneration Meeting, according to an OphthoTech Corporation media release.
    • 24 Jul 2014 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top